Research

Research

PharmaCept GmbH does not have any research laboratories at its disposal. Nevertheless, from the beginning we have strived to combine our sales activities with dependable, feasible research projects. Therefore we saw and continue to see our strong points in conducting field studies within the framework of Phase IV projects with our compounds.

Even though the area of clinical research of the compounds has been regulated for the last 30 years, there are still a number of unanswered questions. This particularly concerns their usage in combination with modern substances. In special circumstances of everyday clinical practices such combinations can be of great importance, for example in the treatment of prostate cancer, where due to lack of alternatives one increasingly considers the application of Estramustine; whereat at the same time there is a shortage of well-grounded, scientific data relating to theoretically reasonable combinations or, in our view, such data has not yet been sufficiently analysed.
Within the field of chemoembolisation, in the last 50 years one has not succeeded in creating worldwide-recognised standards. Only in the area of treatment of the primary liver cell carcinoma has there been a cohesive statistical data collection, raised to the rank of appropriate guidelines. However, details regarding issues of the selected materials, substances and their dosages are still unclear. Here we were able to create further fundamental principles that led us to a better understanding of the processes, including, among other things, the visibly increased accumulation of active substances within the tissues affected by tumour with the addition of our biodegradable embolisation materials, as opposed to therapies with no embolus applied. Further research projects aimed at improving the understanding of similar basic processes are due to start this year.

This kind of experimental and clinical research is possible for PharmaCept GmbH only in cooperation with other interested companies and research groups. Therefore we call upon all interested parties to sit down with us and jointly get involved in thoughtful cooperation in order to seek further solutions.